IGM Biosciences Inc . (NASDAQ:IGMS) stock has tumbled to a 52-week low, reaching a price level of just $1.59 USD. With a ...

In yet another early year blow for the Bay Area’s biotech workforce, IGM Biosciences is laying off almost three-fourths of ...

Stock tumbles to continue slide that started after the company switched to autoimmunity from oncology late last year IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after ...

IGMS stock opened at $2.09 on Friday. The stock has a 50-day simple moving average of $8.94 and a two-hundred day simple moving average of $10.92. IGM Biosciences has a twelve month low of $1.87 ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector perform rating in a report released on Friday, MarketBeat.com reports. The ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...

MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...